Overview

Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or persistent carcinoma of the cervix.
Phase:
Phase 3
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Treatments:
Cisplatin